Onco Actu du 19 septembre 2017

	4. Dépistage, diagnostic et pronostic
Whole-body scans benefit people with highest inherited cancer risk [Institute of Cancer Research] The findings, published in the journal Familial Cancer, suggest the benefits for people with TP53 mutations in detecting and investigating harmless growths such as cysts.
Blood testing via sound waves may replace some tissue biopsies [MIT] Microfluidic device uses acoustics to quickly analyze blood for signatures of cancer and other diseases.
	4.13 Dép., diag. & prono. - Peau
Testing metabolites in blood predicts success of skin cancer treatment [Institute of Cancer Research] A team led by scientists at The Institute of Cancer Research, London, examined blood samples from 35 patients with advanced melanoma who had been treated with a MEK inhibitor called RO4987655. The study was funded by Cancer Research UK and is published in the journal Molecular Cancer Therapeutics.
	5.12.4 Immunothérapies - Essais
FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths [FiercePharma] The partial clinical hold on Tecentriq comes as Roche works to compete with top players in the burgeoning immuno-oncology field, notably against Keytruda and Opdivo. AstraZeneca has also entered the fray with its Imfinzi, and Pfizer and Merck KGaA with Bavencio.
	5.12.5 Immunothérapies - Pharma
Drugmakers Aim at Early Stage Cancer With Immunotherapy [Bloomberg] The drugmakers will first need to convince doctors that the therapies’ price tags -- they cost about $100,000 to $150,000 for a year of treatment -- are worth it, when patients with early stage cancer can benefit significantly from existing treatments.
	5.2 Pharma
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan [Roche] Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting.
AbbVie and Roche tout a positive PhIII combo study of Venclexta, Rituxan in CLL — ahead of FDA pitch [EndPoints] Expanding the number of FDA OKs for this drug is crucial to AbbVie’s plan to expand revenue from about $125 million this year to as much as $1.5 billion to $2 billion a year by the end of the decade. The drug was originally approved for patients with CLL with 17p deletion back in April of 2016.
	5.2.2 Pharma - Fusions & Acquisitions
So Much PARP Inhibitor Deal Hype, So Little Payoff [Bloomberg] There's still a chance a company could take the PARP M&A plunge, and Clovis is the most likely candidate for a buyout with its $3.72 billion market cap. It would cost less than rival Tesaro -- which sports a $6.4 billion market cap -- even if an acquirer pays a significant premium.
	5.2.3 Pharma - économie
Biosimilar cancer drug threat closing in for Roche [Reuters] So far, Roche has seen little impact from the arrival of biosimilar MabThera in Europe, a company spokeswoman said. The first impact from Herceptin biosimilars is expected by the end of this year. But experts believe the pressure will grow steadily.
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy [Bloomberg] Of seven so-called biosimilar drugs the FDA has cleared since the first approval of one of the drugs in 2015, only three are available for sale. The rest are tied up in legal disputes that can block the cheaper versions for years.
	5.3 Traitements - FDA, EMA, NICE...
Standing together: Supercharging the clinical trial in Europe [Pharmafile] The European Medicines Agency is on the cusp of rolling out one of the most ground-breaking digital platforms for facilitating collaboration and efficiency in clinical trials. Matt Fellows talks with the agency on how it will work, how it will change the game, and why it is not fazed by the recently announced delay on its rollout.
	5.3.4 Traitements - AMM (FDA, EMA)
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome [Ipsen] Somatuline® Depot is also approved for the improvement of progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma [Cancer Research Catalyst] The approval of copanlisib for treating adults with follicular lymphoma that has returned after two or more systemic treatments makes it the sixth treatment approved for patients with hematological malignancies since the start of August.
FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic Leukemia [NCI] The approval, announced on August 17, is for the use of inotuzumab in patients with B-cell ALL whose disease has stopped responding to (relapsed) or never responded to (refractory) standard chemotherapy.
	6. Lutte contre les cancers
Peter Pisters officially named president of UT MD Anderson [university of Texas] Pisters is a renowned cancer surgeon, researcher and health care administrator who has overseen the largest hospital-based research program in Canada since January 2015.
	6.1 Observation
People with HIV who smoke are more likely to die from lung cancer than from HIV itself [Mass. General Hospital] MGH-led study estimates that nearly 10 percent of people with HIV currently in care in the U.S. will die from lung cancer.
Smokers with HIV face higher risk from lung cancer than from AIDS [Reuters] “Today, the number one killer of people with HIV on treatment in the U.S. is not the virus, it’s smoking.”
	6.13 Soins palliatifs
End-of-life decisions can be difficult. This doctor thinks ‘nudges’ can help [STAT] Clinicians frequently offer seriously ill patients the option of completing an advance directive, to help establish their goals of care. Most patients end up not doing so, because inertia gets in the way. But framing can help a lot.